Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Jonsson Comprehensive Cancer Center
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07619313CT.gov AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer | — | Not Yet Recruiting | — | — | — |
NCT05927142CT.gov Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy | — | Recruiting | — | — | — |
NCT05411094CT.gov Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer | — | Suspended | — | — | — |
NCT05659914CT.gov Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations | — | Active Not Recruiting | — | — | — |
NCT05187338CT.gov Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT04940286CT.gov Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer | — | Active Not Recruiting | — | — | — |
NCT04257448CT.gov Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer | — | Completed | — | — | — |
NCT04156087CT.gov Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer | — | Completed | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT04005690CT.gov Targeted Pathway Inhibition in Patients With Pancreatic Cancer | — | Recruiting | — | — | — |
Show 8 more trialsShow fewer
NCT03682289CT.gov Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03376659CT.gov Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | — | Terminated | — | — | — |
NCT03257761CT.gov Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer | — | Active Not Recruiting | — | — | — |
NCT02885727CT.gov Durvalumab Plus "Booster" RT for Metastatic Adenocarcinoma Pancreas Cancer Post Chemotherapy (GCC 1598) | — | Withdrawn | — | — | — |
NCT02983578CT.gov Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT02669914CT.gov MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | — | Terminated | — | — | — |
NCT02734160CT.gov A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer | — | Completed | — | — | — |
NCT02311361CT.gov Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Malignant Pancreatic Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Durvalumab (this asset) | Jonsson Comprehensive Cancer Center | P2 | BB · 66 |
| Immunoglobulin G1, Anti-(Humanized Mouse Monoclonal Hr3 .Beta.1 Chain Anti-Human Epidermal Growth Factor Receptor), Disulfide With Humanized Mouse Monoclonal Hr3 .Kappa.-Chain, Dimer | Chinese PLA General Hospital | P4 | BBB |
| Metformin | State University of New York - Downstate Medical Center | P2 | BBB |
| Fluorouracilum | Jonsson Comprehensive Cancer Center | P4 | BBB |
| Irinotecan | Jonsson Comprehensive Cancer Center | P3 | BB |
| Oxaliplatin | Jonsson Comprehensive Cancer Center | P4 | BB |
| Cis-Diamminedichloroplatinum Ii | Jonsson Comprehensive Cancer Center | P2/3 | BB |
| Olaparib | MOMA Therapeutics | P2 | BB |
| Tunlametinib | Chinese PLA General Hospital | P4 | BB |
+42 more in the Malignant Pancreatic Neoplasm cohort
Other indications for Durvalumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Carcinoma | — | P2 | BB · 70 |
| Primary Peritoneal Carcinoma | — | P2 | BB · 70 |
| Urothelial Carcinoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Immunoglobulin G1, Anti-(Humanized Mouse Monoclonal Hr3 .Beta.1 Chain Anti-Human Epidermal Growth Factor Receptor), Disulfide With Humanized Mouse Monoclonal Hr3 .Kappa.-Chain, DimerChinese PLA General HospitalBBB
- MetforminState University of New York - Downstate Medical CenterBBB
- FluorouracilumJonsson Comprehensive Cancer CenterBBB
- IrinotecanJonsson Comprehensive Cancer CenterBB
- OxaliplatinJonsson Comprehensive Cancer CenterBB
Citation
Floatz Terminal. Durvalumab in Malignant Pancreatic Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/durvalumab-malignant-pancreatic-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →